John R. Ingrassia

Proskauer (Washington)
Special Counsel

John R. Ingrassia is Senior Counsel at Proskauer Rose. John is a recognized authority on Hart-Scott-Rodino antitrust merger review, and for more than 20 years has counselled businesses facing the most challenging antitrust issues and helped them stay out of the crosshairs — whether its distribution, pricing, channel management, mergers, acquisitions or joint ventures. John is a senior counsel at the Firm, advising on the full range of antitrust matters in diverse industries, including chemicals, pharmaceutical, medical devices, telecommunications, financial services and health care, among others. His practice focuses on the analysis and resolution of antitrust issues related to mergers, acquisitions, and joint ventures, and the analysis and assessment of pre-merger notification requirements. John has extensive experience with the legal, practical, and technical requirements of merger clearance and is regularly invited to participate in Federal Trade Commission and bar association meetings regarding Hart-Scott-Rodino practice issues. John also advises clients on issues related to CFIUS national security reviews, and on CIFIUS submissions when non-U.S. buyers seek to acquire U.S. businesses that have national security sensitivities. This is an area of significant focus under the current administration as new trade and foreign investment policies continue to take shape.

Distinctions

Linked authors

Squire Patton Boggs (Washington)
Proskauer (Washington)
Proskauer (Washington)
Proskauer (New York)

Articles

136 Bulletin

Alicia J. Batts, Christopher E. Ondeck, Colin Kass, David Munkittrick, John R. Ingrassia The U.S. District Court for the Northern District of Ohio denies the FTC bid for a preliminary injunction in a merger case (Steris / Synergy)

136

"Prophesy is a good line of business, but it is full of risks." Mark Twain could have been speaking about the FTC’s recent challenge to a merger between the second- and third- largest sterilization companies in the world, Steris Corporation and Synergy Health. FTC v. Steris Corp., 2015 WL (...)

Send a message